Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B).
Yee M, Lin Y, Gorantla V, Butterfield L, Kluger H, Chapman P, Gangadhar T, Milhem M, Pavlick A, Amaravadi R, Schuchter L, Tarhini A, Kirkwood J, Tawbi H. Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B). Journal Of Clinical Oncology 2015, 33: tps9088-tps9088. DOI: 10.1200/jco.2015.33.15_suppl.tps9088.Peer-Reviewed Original ResearchActive melanoma brain metastasesMelanoma brain metastasesPhase 2 studyBrain metastasesCobimetinibMetastasisVemurafenib